Proteostasis Therapeutics Inc. (PTI) and Its Peers Financial Results Comparison

Proteostasis Therapeutics Inc. (NASDAQ:PTI) is a company in the Biotechnology industry and that’s how we compare it to its rivals. The contrasting will be based on the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Institutional & Insider Ownership

Proteostasis Therapeutics Inc. has 47.6% of its shares held by institutional investors vs. an average of 50.88% institutional ownership for its peers. 0.5% of Proteostasis Therapeutics Inc. shares are held by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are held by company insiders.


Table 1 has Proteostasis Therapeutics Inc. and its rivals’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Proteostasis Therapeutics Inc. -1,308.52% -104.10% -76.70%
Industry Average 1,464.25% 88.44% 21.62%

Valuation and Earnings

In next table we are contrasting Proteostasis Therapeutics Inc. and its rivals’ net income, valuation and gross revenue.

Net Income Gross Revenue Price/Earnings Ratio
Proteostasis Therapeutics Inc. 58.36M 4.46M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 provides summary of recent ratings for Proteostasis Therapeutics Inc. and its rivals.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Proteostasis Therapeutics Inc. 0 0 3 3.00
Industry Average 1.17 1.78 2.01 2.68

$17.5 is the consensus price target of Proteostasis Therapeutics Inc., with a potential upside of 344.16%. The potential upside of the rivals is 173.20%. With higher probable upside potential for Proteostasis Therapeutics Inc.’s rivals, analysts think Proteostasis Therapeutics Inc. is less favorable than its rivals.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Proteostasis Therapeutics Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteostasis Therapeutics Inc. -6.11% -31.11% 94.29% 60.27% 88.14% -18.35%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Proteostasis Therapeutics Inc. has -18.35% weaker performance while Proteostasis Therapeutics Inc.’s rivals have 65.27% stronger performance.


The Current Ratio and a Quick Ratio of Proteostasis Therapeutics Inc. are 4.2 and 4.2. Competitively, Proteostasis Therapeutics Inc.’s peers have 7.68 and 7.52 for Current and Quick Ratio. Proteostasis Therapeutics Inc.’s rivals have better ability to pay short and long-term obligations than Proteostasis Therapeutics Inc.


Proteostasis Therapeutics Inc. does not pay a dividend.


Proteostasis Therapeutics Inc.’s rivals beat on 3 of the 4 factors Proteostasis Therapeutics Inc.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.